ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESMMAKHTNMD..........*J2.0.21 - 2999001/03886820CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120230517W173deBibliographieenBibliographyfrBibliographieEP19889873.62019112720210617enenen201862773848 P20181130US2023051720232020211006202140202304122023152023010220230517202320A61K 9/48 20060101AFI20220722BHEP A61K 31/451 20060101ALI20220722BHEP A61K 47/10 20170101ALI20220722BHEP A61K 47/14 20170101ALI20220722BHEP A61K 47/40 20060101ALI20220722BHEP A61K 47/44 20170101ALI20220722BHEP A61K 9/4858 20130101 LI20200630BHEP A61K 9/4825 20130101 FI20200630BHEP A61K 47/10 20130101 LA20200630BHEP A61K 47/14 20130101 LA20200630BHEP A61K 47/40 20130101 LA20200630BHEP A61K 47/44 20130101 LA20200630BHEP A61K 31/451 20130101 LI20220627BHEP deKAPSELFORMULIERUNGENenCAPSULE FORMULATIONSfrFORMULATIONS DE CAPSULESUS-A1- 2007 298 099US-A1- 2010 311 753US-A1- 2017 246 186US-A1- 2018 179 160US-A1- 2018 280 530BEKKER et al.: "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS One, vol. 11, no. 10, 21 October 2016 (2016-10-21), pages 1-19, XP055602780,2022072723160271.520230306LELETI, Manmohan Reddy4205 Kelton StreetDublin, California 94568USPOWERS, Jay P.745 Rockaway Beach AvenuePacifica, California 94044USChemoCentryx, Inc.101991080N421934EPOne Amgen DriveThousand Oaks, CA 91320USJ A Kemp LLP10166966680 Turnmill StreetLondon EC1M 5QUGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20210617ME20210617KH20210617MA20210617MD20210617TN20210617US201906354720191127enWO202011296120200604202023